Durable reprogramming of neutralising antibody responses following breakthrough Omicron infection
Lee, W. S.; Tan, H.-X.; Reynaldi, A.; Esterbauer, R.; Koutsakos, M.; Nguyen, J.; Amarasena, T.; Kent, H. E.; Aggarwal, A.; Turville, S. G.; Taiaroa, G.; Kinsella, P.; Liew, K. C.; Tran, T.; Williamson, D. A.; Cromer, D.; Davenport, M. P.; Kent, S. J.; Juno, J. A.; Khoury, D. S.; Wheatley, A. K.
Show abstract
SARS-CoV-2 breakthrough infection of vaccinated individuals is increasingly common with the circulation of highly immune evasive and transmissible Omicron variants. Here, we report the dynamics and durability of recalled spike-specific humoral immunity following BA.1 or BA.2 breakthrough infection, with longitudinal sampling up to 8 months post-infection. Both BA.1 and BA.2 infection robustly boosted neutralisation activity against the infecting strain while expanding breadth against other Omicron strains. Cross-reactive memory B cells against both ancestral and Omicron spike were predominantly expanded by infection, with limited recruitment of de novo Omicron-specific B cells or antibodies. Modelling of neutralisation titres predicts that protection from symptomatic reinfection against antigenically similar strains will be remarkably durable, but is undermined by novel emerging strains with further neutralisation escape. One sentence summaryOmicron breakthrough infection elicits durable neutralising activity by recalling cross-reactive vaccine-elicited memory B cells.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Antigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153 96%
- Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals 96%
- The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD 96%
Similar papers in this journal
- Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity in uninfected and previously infected individuals 96%
- Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without Vaccination 95%
- High number of SARS-CoV-2 persistent infections uncovered through genetic analysis of samples from a large community-based surveillance study 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.